We have previously demonstrated that the 21-residue peptide pMOG 35±55 from myelin oligodendrocyte glycoprotein (MOG) contains an antigenic epitope that activates CD8 + encephalitogenic T cells in C57BL/6 (B6) mice. To identify the core encephalitogenic epitope of CD8 + MOG-speci®c T cells, we have prepared a panel of highly puri®ed peptides of varying lengths, which span the entire length of pMOG 35±55 , and tested their binding to recombinant H-2D b dimers and their ability to induce EAE. Two of the truncated peptides, pMOG 40±54 and pMOG 44±54 , strongly bound recombinant H-2D b protein and this complex bound MOG-speci®c CD8 + T cells. Interestingly, pMOG 40±54 retained the full capability of inducing paralytic disease, whereas only a part of the B6 mice immunized with pMOG 44±54 developed clinical paralysis and central nervous system (CNS) in¯ammation. Further deletion of 1 amino acid from either the N-or C-terminus of the peptide pMOG 44±54 dramatically reduced binding to recombinant H-2D b , and abolished the induction of paralysis and CNS in¯ammation. Our results demonstrate that the ability of truncated pMOG 35±55 peptides to bind recombinant H-2D b protein does not always correlate with their ability of inducing encephalomyelitis. This approach enables the further identi®cation of the core pathogenic epitope within the pMOG 35±55 that activates MOG-speci®c encephalitogenic CD8 + T cells.
Introduction
Experimental autoimmune encephalomyelitis (EAE) has been induced in rodents by sensitization to a number of myelin proteins, including myelin basic protein (MBP) (1±3), proteolipid protein (PLP) (4±5), myelin oligodendrocyte glycoprotein (MOG) (6±8), myelin-associated glycoprotein (9) and myelin oligodendrocyte basic protein (10) . Previous studies of the functional characteristics of encephalitogenic effector cells during EAE have focused on T lymphocytes that react with MBP and PLP. These studies have led to the general consensus that, unlike autoimmune diabetes in which both CD4 + and CD8 + T cells participate in the causation of disease (11±13), effector T cells in EAE are exclusively CD4 + and abTCR + (14) .
In a previous study, we have shown that immunization of B6 mice with a synthetic peptide corresponding to residues 35± 55 of MOG (pMOG 35±55 ) persistently induced a MOG-speci®c CD8 + T cell subset that has an increased ability to induce paralytic demyelinating disease in B6 mice. Such T cells could be readily identi®ed by FACS analysis based on their ability to bind complexes of H-2D b and pMOG 35±55 (15) . Since typical antigenic epitopes for CD8 + T cells are composed of 9±10 amino acids (16, 17) , we have analyzed the ability of peptides scanning the length of pMOG 35±55 to bind recombinant H-2D b dimers and to induce paralysis in order to identify the core epitope structure of pMOG 35±55 -speci®c encephalitogenic CD8 + T cells. In the present study, we show that both of the truncated peptides pMOG 40±54 and pMOG 44±54 in complexes with H-2D b strongly bound MOG-speci®c CD8 + T cells in vitro; however, only pMOG 40±54 retained a full capability of inducing clinical and pathological changes in B6 mice in vivo, indicating that pMOG 44±54 may have lost some stimulatory function necessary for development and/or expansion for CD8 + encephalitogenic T cells, even though it retains the ability to bind these T cells.
Methods

Animals
C57BL/6J (B6) mice were obtained from Jackson Laboratories (Bar Harbor, ME) and housed in an NIH-approved and AAALAC-accredited facility.
Cells and reagents
All T cells were cultured in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 10% selected FCS (Gibco), 5 Q 10 ±5 M 2-mercaptoethanol and penicillin/streptomycin (100 mg/ml). Synthetic peptides listed in Table 1 were produced by the Shriners Hospital for Children, Montreal, Canada. These peptides were synthesized using standard Fmoc chemistry on an Applied Biosystems model 433A solid-phase peptide synthesizer. All the peptides were HPLC puri®ed. The authenticity of these peptides was con®rmed by the amino acid composition analyses and by mini-sequencing of the N-terminal up to 15 amino acids of the HPLC-puri®ed protein.
Recombinant dimers of the MHC class I (H-2D b ) molecule recombinant human b 2 -microglobulin were obtained from BD Biosciences PharMingen (San Diego, CA).
MOG-speci®c T cell hybridomas were prepared as we previously reported (15) . Brie¯y, MOG-speci®c T cell lines were prepared and residual CD4 + T cells were completely removed by magnetic beads conjugated with anti-mouse CD4 antibodies. A mini-fusion between a CD8 + MOG-speci®c T cell line and a variant line of BW5147 (18) has yielded >40 growing hybridomas, of which 20 were randomly selected for analysis of binding activity against pMOG 35±55 -bound H-2D b molecules. One of the hybrids (MOG-TH10) was chosen for this study.
Active induction of EAE
Mice were immunized with MOG peptides (200 mg per mouse) emulsi®ed in complete Freund's adjuvant (CFA) containing 0.6 mg Mycobacterium tuberculosis (H37Ra; Difco, Detroit, MI). One day post-immunization, MOG-sensitized animals received a single dose of 400 ng of Pertussis toxin i.p. (Sigma, St Louis, MO).
Isolation of T cells from B6 mice with EAE actively immunized with MOG peptides
To determine and characterize encephalitogenic T cells from animals immunized with MOG peptides, T cells isolated from the draining lymph nodes and spleens of immunized animals were enriched by passage through nylon wool and restimulated in vitro with immunizing peptides (20 mg/ml) presented by irradiated syngeneic spleen cells. After 3 days, activated T cell blasts were separated on a Ficoll gradient and injected (2 Q 10 6 , i.p.) into naive B6 mice.
T cell proliferation/inhibition assays
Antigen-presenting cells (APC, irradiated syngeneic spleen cells, 2 Q 10 5 /well) were pre-incubated in 96-well¯at-bottom microtiter plates with an optimal dose (20 mg/ml) of pMOG 35± 55 . After 1 h, enriched T cells (4 Q 10 5 /well), prepared from lymph nodes or spleen by nylon wool adhesion, were seeded and further incubated for 48±72 h. The cultures were then pulsed with 1.0 mCi [ 3 H]thymidine/well for 6 h, harvested and the incorporated isotope quantitated by liquid scintillation.
Depletion of T cell subsets by antibody-coated magnetic beads
Nylon wool-enriched splenic T cells were incubated with 10 mg/ml of either rat anti-mouse CD4 mAb (GK1.5) or normal rat Ig (control) for 30 min. Unbound antibody was removed by twice washing before the addition of magnetic biospheres coupled to goat anti-rat Ig (BioSource, Camarillo, CA), incubation at 4°C and agitation for 30 min. The tube of cells was then placed on a magnetic stand for 5 min and cells free of magnetic particles were collected. The procedure was repeated 2±3 times, as necessary.
Evaluation of EAE
Animals were examined daily for weight loss and clinical signs. Animals were clinically graded as follows: 0 = no signs, 1 = partial loss of tail tonicity, 2 = loss of tail tonicity, dif®culty in righting, 3 = unsteady gait and mild paralysis, 4 = hind-limb paralysis and incontinence, and 5 = moribund or death.
Flow cytometric detection of T cells binding to pMOG 35±55 complexed with recombinant dimers of MHC class I (H-2D b ) molecule
Dimeric MHC class I (H-2D b ) used in this study is a fusion protein between mouse H-2D b and mouse IgG1. The recombinant protein was added to an equal amount of human b 2 -microglobulin at a ®nal concentration of 0.15 mg/ml, in the presence of an excess amount of testing peptide (1 mg/ml). The mixtures were stored at 4°C for 24±48 h before use. Dual-color staining was performed by incubating 5 Q 10 5 cells with peptide dimer complexes of 1.0 mg per staining at 4°C for 30 min. The cells were washed twice in PBS containing 1% BSA and 0.1% sodium azide, and re-stained with a phycoerythrin (PE)-labeled anti-mouse IgG1 antibody, followed by a subsequent staining with FITC-conjugated antibody. The results are presented as FITC (x-axis) versus PE (y-axis) staining.
Results
MOG-speci®c CD8 + T cells recognize complexes of pMOG 40±54 and pMOG 44±54 peptides and dimeric MHC class I (H-2D b ) molecules
We have previously reported that a major population of encephalitogenic MOG-speci®c T cells in the B6 mouse expresses CD8 and abTCR. This CD8 + T cell subset can be readily identi®ed by their ability to bind complexes of pMOG 35± 55 polypeptide and recombinant H-2D b protein as assessed by¯ow cytometry (15) . The frequency of pMOG 35±55 -reactive T cells is estimated to be <1% of the total T cell population in the lymphoid organs of immunized mice (not shown). Following antigenic stimulation in vitro and expansion in medium supplemented with IL-2, the percentage of MOGspeci®c T cells increases rapidly ( Fig. 1) (15) .
The length of pMOG 35±55 polypeptide (21mer) is about twice the size of a peptide that has been shown to ®t into the MHC class I groove using molecular and structural approaches (16, 17) . The binding of MOG-speci®c CD8 + T cells to recombinant H-2D b dimers in the presence of truncated pMOG 35±55 peptide was investigated to identify the core epitope(s) critical to the recruitment of this population in the pathogenesis of encephalomyelitis by MOG peptides. Therefore, we designed a panel of truncated peptides that linearly scanned pMOG 35±55 (Table 1) . Since MOG-speci®c CD8 + T cell subsets may vary in their ability to bind peptide± MHC I complexes, MOG-speci®c T cell hybridomas served as target cells. These cell lines were generated by fusion of highly enriched primary MOG-speci®c CD8 + T lymphocytes to a variant of the BW5147 thymoma line that lacks both the a and b chain of the TCR (19) . Several stable T hybridoma cell lines were obtained that speci®cally bind pMOG 35±55 in complex with H-2D b dimers.
Nylon wool-enriched splenic T cells from mice immunized with pMOG 35±55 were stimulated with this peptide and expanded in IL-2-containing medium for 5±7 days. Approximately 40±60% of the abTCR + lymphoid cells in this population bound PE-labeled pMOG 35±55 ±H-2D b complexes [ Fig. 1 and (15) ]. The scanning peptides varied greatly in their ability to mediate binding between T cell and dimeric H-2D b protein. The pMOG 40±54 peptide interacted with recombinant PE-labeled H-2D b protein and this complex bound primarily MOG-speci®c CD8 + T cells at high levels, as shown in Fig. 1 . This observation was extended in binding experiments using the MOG-TH10 cell, a MOG-speci®c CD8 + T cell hybridoma, as targets (Fig. 2) . Studies of a panel of truncated peptides A key question is whether the ability of truncated peptides that scan pMOG 35±55 sequences and bind MOG-speci®c CD8 + T cells in complex with H-2D b ±PE re¯ects their ability to induce paralytic disease in vivo. We have also determined the ability of these peptides to induce activated T lymphocytes that can adoptively transfer EAE. Three groups (n = 10) of B6 mice were immunized with pMOG 40±54 , pMOG 44±54 or pMOG 35±55 (200 mg emulsi®ed in 50 ml CFA). T cells speci®c for the immunizing peptides (2 Q 10 6 ) were isolated 2±3 weeks after the immunization and transferred to groups of naive B6 mice. As summarized in Table 3 , paralysis developed in two out of 10 mice that received pMOG 44±54 -speci®c T cells and in 14 of 16 mice that received pMOG 40±54 -speci®c T cells. The paralysis following transfer from mice immunized with pMOG 40±54 was complete, whereas it was partial in those receiving T cells elicited by pMOG 44±54 . We also determined the central nervous system (CNS) in¯ammatory reaction induced by the peptides using a routine pathological examination method as well as Fast Luxol blue staining. As demonstrated in Fig. 3(A±C) , pMOG 40±54 induced an intense CNS in¯ammatory in®ltration that was similar in composition and magnitude to that observed in mice receiving pMOG 35±55 (15) ; in¯ammation induced by pMOG 44±54 was marginal.
The truncated MOG peptide pMOG 40±54 was more potent in eliciting T cell responses than pMOG 44±54 We determined whether T cells induced by the truncated peptides share antigenic speci®city with those T cells induced by pMOG 35±55 and whether the binding ability of the truncated MOG peptides paralleled their T cell stimulating activity. To test this, B6 mice were randomly grouped and immunized with pMOG 40±54 , pMOG 44±54 and pMOG 35±55 . Two weeks after immunization, T cells obtained from the spleen and draining lymph nodes of immunized mice were enriched and confronted with a panel of selected MOG-derived peptides (see Table 1 ) in the presence of irradiated APC. As demonstrated in Fig. 3 peptide that binds to CD8 + MOG-speci®c T cells and stimulates T cell proliferation in vitro.
Discussion
The intensity of antigen-speci®c T cell responses is usually measured by limiting dilution analysis (LDA), which determines the number of antigen-speci®c T cells (20±22). Because the assay does not detect those T cells that fall into a refractory phase of the T cell cycle, LDA may underestimate the number of T cells recognizing certain peptides. To complement LDA, a new experimental tool has been discovered to directly enumerate antigen-speci®c T cells by their binding of peptide±MHC complexes, thus obviating the need to rely on effector T cell activities. Staining antigen-speci®c T cells with¯uorescent-labeled tetrameric MHC±peptide complexes has provided a powerful experimental tool to characterize the intensity of an immune response (23±26). The binding assays have been applied to quantify virus-speci®c cytotoxic T cells (25, 27, 28) , T cells that are speci®c for tumor-associated antigen (29) and CD4 + autoreactive T cells (30±33). In such studies, peptide±MHC complexes were most often engineered as tetramers, with addition of a substrate peptide for BirA-dependent biotinylation to the C-terminus of the heavy chain of the MHC molecule. After folding in vitro the heavy chain fusion protein in the presence of b 2 -microglobulin and a speci®c peptide ligand was biotinylated on the lysine within the BirA substrate peptide. Tetramers were produced by mixing the biotinylated peptide±MHC complex with PE-labeled deglycosylated avidin at a molar ratio of 4:1 (27, 34) .
Dimeric MHC molecules can also be used. For the dimeric peptide±MHC complex the recombinant light (b 2 -microglobulin) and heavy chains can be folded in vitro with different antigenic peptides, whereas their tetrameric counterparts are pre-conjugated with one chosen antigenic peptide. In the present study, we applied this unique feature of dimeric MHC molecules to de®ne epitopes of antigen-speci®c CD8 + T cells. In a previous report, we have demonstrated that synthetic peptides encompassing residues 35±55 of the MOG readily activated a CD8 + abTCR + encephalitogenic T cell subset(s) in B6 mice and that this subset of MOG-speci®c T cells induced a paralytic disorder and caused CNS in¯ammation (15) . Remarkably, as few as 10 6 CD8 + MOG-speci®c T cells administered to naive B6 mice could be readily retrieved 6± 10 months after adoptive transfer (15) , indicating that the Adoptively EAE was transferred by i.p. injection of 2 Q 10 6 peptide-speci®c T cells that had been exposed to the peptide immunogen (20 mg/ml) for 3 days in vitro. 40±54 8/10 14±16 2±4 pMOG 44±54 3/10 18±20 1±2 pMOG 44±53 0/10 NA NA pMOG 45±54 0/10 NA NA Active EAE was induced by immunization of recipient animals s.c. with 200 mg indicated peptides in the complete adjuvant containing 0.6 mg M. tuberculosis (H37Ra). The animals were analyzed for weight loss and clinical manifestations of paralysis as detailed in Methods.
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at Pennsylvania State University on February 23, 2013 http://intimm.oxfordjournals.org/ Downloaded from CD8 + encephalitogenic T cells survived for long periods in vivo and their appearance was closely associated with progression of disease. Notably, MOG induced a chronic progressive disease and pathologic demyelination, which closely resembled secondary progressive MS, the most common form of disabling MS (7, 35) .
Our previous observation showed that CD8 + MOG-speci®c T cells recognize H-2D b dimers when loaded with an encephalitogenic peptide (pMOG 35±55 ). Such binding activity can easily be monitored by a¯uorescent-binding assay (15) . We ®rst asked whether such binding assays could be exploited for prediction of the functional epitope of myelinspeci®c CD8 + T cells. We were particularly interested to learn whether all MOG peptides that possessed binding activity to MOG-speci®c CD8 + T cells were able to induce paralytic pathology in B6 mice. Surprisingly, the truncated MOG peptides bound better in the absence of the lysine at position 55. Peptides pMOG 35±53 and pMOG 44±53 did not differ appreciably in binding, indicating that the amino acids at positions 35±43 did not play a critical role in binding. In contrast, the lack of glycine at position 54 in these two peptides dramatically decreased their binding activity, indicating that this amino acid was functionally critical. The fact that pMOG 35±53 lost most of its binding activity reinforced the conclusion that the glycine at position 54 was functionally essential.
We next determined whether truncation of pMOG 40±54 from the N-terminal modi®ed the peptide's functional activity. The second panel of peptides (Table 1 Panel B) was designed by further truncation of the N-terminus of pMOG 40±54 while preserving the C-terminus (residue 54) of the peptide. Our results have shown that the minimal peptide length required for binding to CD8 + MOG-speci®c T cells was the MOG peptide containing residues 44±54 (FSRVVHLYRNG).
The disease-inducing activity of the truncated MOG peptides does not completely match the binding activity. Encephalitogenic activity was completely abolished in the absence of residues 44±45, even though variable binding activity remained. In addition, pMOG 44±54 retained a strong binding activity, yet only some of the naive B6 mice immunized with this peptide were rendered paralytic. Only three out of 10 mice immunized with pMOG 44±54 developed clinical EAE, compared to 80±90% of the mice immunized with pMOG 35±55 or pMOG 40±54 . Proliferation assays agreed with the relative abilities of peptides to induce disease since the partially truncated 15mer pMOG 40±54 induced a strong T cell response in vivo and in vitro, while the 11mer pMOG 44±54 was weaker. It appears that residues 40±43 play a major role in eliciting a strong T cell response, but are not mandatory for binding. Conceivably, peptides >12 amino acids may activate both CD8 + and CD4 + T cellsÐwith the latter providing`help' for the activation and/or expansion of CD8 + T cells, whereas the binding assay does not require help fro CD4 + T cells. Thus, we conclude that: (i) the binding assays are a useful tool for revealing core antigenic epitopes of CD8 + T cells and (ii) the optimal encephalitogenic peptide of MOG may be longer than the peptide needed for the binding of CD8 + T cells.
Thus far, we were unable to de®ne separate antigenic epitopes speci®c for CD4 or CD8 T cells, because pMOG 40±54 retained both CD4 and CD8 stimulatory activity, whereas pMOG 44±54 dramatically lost activity in stimulating either T cells (data not shown). The available data appear to support the notion that only the MOG peptides capable of activating both CD4 and CD8 cells acquired encephalitogenic activity. Indeed, such a hypothesis has also been supported by our recent study using established CD4 + pMOG 35±55 -speci®c T cell lines, which responded to both pMOG 35±55 and pMOG 40± 54 , but not pMOG 44±54 . It remains undetermined whether pMOG 40±54 contains two separate epitopes for CD4 and CD8 T cells respectively.
In summary, we have determined the binding activity of truncated MOG peptides to CD8 + encephalitogenic T cells and H-2D b molecules, and compared their binding activity with the encephalitogenic potential of the peptides. Our results showed that the pMOG 44±54 (FSRVVHLYRNG) is the minimal binding epitope for the CD8 + MOG-speci®c T cell. Addition of amino acids at positions 40±43 augmented T cell stimulation and disease induction, but not necessarily the binding activity of the peptide. Our studies indicated that the binding assay of using dimeric MHC molecules is a useful tool for prediction of the functional epitope of CD8 + autoreactive T cells. The optimal or maximal induction of CD8 + autoreactive T cells may require the help of CD4 + T cells. 
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